-
ED generic drugs have quality problems!
Time of Update: 2021-12-06
Now, this company is in big trouble!According to the latest enforcement report of the US FDA, the Mumbai-based Indian pharmaceutical giant is recalling over 110,000 bottles of tadalafil generic drugs in the US market through its US branch due to production quality problems .
-
Gao Xuemin, independent director of Watson Pharmaceuticals, leaves Li Hui as candidate for by-election
Time of Update: 2021-12-06
On November 17, Watson Pharmaceuticals issued an announcement stating that as his term of office expires on November 15, Gao Xuemin will no longer serve as independent director of the company’s second board of directors and chairman of the second board’s nomination committee, and his resignation will be in Effective from the day when the company’s general meeting of shareholders elects new independent directors .
-
Huahai Pharmaceutical's preparation product Acyclovir ointment was approved by the U.S. FDA
Time of Update: 2021-12-06
Acyclovir ointment was developed by Bausch Health US and was first marketed in the United States in 1982 .
-
Sichuan Province issued an important notice, the purchase of oral consumables with quantity or started
Time of Update: 2021-12-06
At present, the Sichuan Pharmaceutical Equipment Bidding and Purchasing Service Center has officially started the information declaration work for the maintenance of dental implants and repair abutment medical consumables.
-
FDA delays Bristol-Myers Squibb's first-in-class cardiomyopathy drug listing application
Time of Update: 2021-12-06
The Phase III clinical results, code-named EXPLORER-HCM, showed that compared with the placebo group, Mavacamten showed clinically significant improvements in symptoms, functional status and quality of life in patients with symptomatic oHCM, reaching all primary and secondary clinical endpoints .
-
The second domestically produced generic drug!
Time of Update: 2021-12-06
It is reported that Hausen Pharmaceutical's fulvestrant is the second generic fulvestrant that was declared and approved by a Chinese company .
Now, after Tianqing, Hausen Pharmaceutical's fulvestrant has become the second domestic generic drug .
-
Many children's drug registration certificates have been cancelled!
Time of Update: 2021-12-06
For example, in China, in recent years, as the issue of children's medication has become a livelihood issue that the country attaches great importance to, in order to increase the research and development enthusiasm of manufacturers, the State Food and Drug Administration, the National Health Commission, and the Medical Insurance Bureau have successively introduced a series of policy measures.
-
The domestic innovative drug track is becoming more and more "involved", what should pharmaceutical companies do?
Time of Update: 2021-12-06
Some popular tracks such as ADC drugs and PD-1 products are becoming more and more "involved", more and more companies are entering the game, and the amount of fundraising and financing is also increasing, and the competition is fierce .
-
Bid opening is coming soon!
Time of Update: 2021-12-05
Specifically, the alliance regions that actually participated in the reporting of drugs in this variety range include the following provinces: Guangdong, Shanxi, Jiangxi, Henan, Hunan, Guangxi, Hainan, Guizhou, Gansu, Qinghai, Ningxia, Xinjiang, Xinjiang Production and Construction Corps, the above provinces are the regions that participated in the procurement of the inter-provincial alliance this time .
-
1.7 billion injections!
Time of Update: 2021-12-05
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
-
Innovation is not easy. Dozens of pharmaceutical companies have suspended or terminated the development of new drugs this year
Time of Update: 2021-12-05
In addition to Merck, according to media statistics, no less than 20 pharmaceutical companies have announced the termination or suspension of research and development in the drug field this year .
-
BeiGene OX40 agonist approved, clinical IL-6 inhibitor is expected to be approved in the near future
Time of Update: 2021-12-05
One is its self-developed class 1 new drug OX40 agonist BGB-A445 injection, which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (CDE) for clinical trials; the second is its introduction of IL-6 inhibitors for injection Stuximab (siltuximab), the new drug listing application review status in China has been updated to: Pending approval, which means that the drug is expected to be approved in China in the near future .
-
API companies are accelerating production expansion, and the pharmaceutical industry in the industry chain is expected to benefit
Time of Update: 2021-12-05
. Therefore, under the background that a large number of raw material pharmaceutical companies have established sites and upgraded and expanded their production, pharmaceutical equipment companies will also usher in more demand, and their market will continue to expand accordingly .
-
Sharing economy promotes the efficient development of Chinese medicine industry
Time of Update: 2021-12-05
With the gradual development of the two pilot provinces of the National Medical Community and the 567 compact county medical community construction pilot projects , To ensure the same quality and same price of regional TCM decoction pieces, and improve the TCM service capabilities of primary medical institutions .
-
Pfizer's new crown oral drug Paxlovid is $529 per course of treatment
Time of Update: 2021-12-05
On October 27th, Merck and its partner Ridgeback announced that they had reached a treatment license agreement with the United Nations to give up patents in 105 low- and middle-income countries around the world to allow them to produce generic drugs .
-
Wuhan starts the "dual channel" management of negotiation drugs, 71 kinds of drugs can be used in hospital pharmacies to apply for medical insurance
Time of Update: 2021-12-05
In order to solve the problem of "difficulty in entering hospitals" for medical insurance negotiation drugs, the two ministries and commissions of the Wuhan Municipal Medical Insurance Bureau issued a notice a few days ago to clearly include designated pharmacies in the scope of the medical insurance negotiation drug supply guarantee, forming a "dual channel" with designated medical institutions.
-
Topical analgesics over 18 billion market, plasters "rule the king", this exclusive Ted product shines
Time of Update: 2021-12-05
Among the TOP5 products of China's public medical institutions, Tide's flurbiprofen gel plaster (Zepusi® Debam®) ranked first, with the highest growth rate and the only chemical drug on the list .
-
Why do pharmaceutical companies repeat the mistakes of Internet medical treatment in digital therapy?
Time of Update: 2021-12-05
. Of course, it is precisely because online consultation and health management are corporate benefits, users are separated from doctors, and digital therapy hopes to promote patients to get one-stop solutions from doctors .
-
Hengrui Medicine: "Bringing in" is more open and "Going out" is not slack
Time of Update: 2021-12-05
On November 21, Hengrui Medicine issued an announcement to reach a cooperation with CStone Pharmaceuticals to introduce anti-CTLA-4 monoclonal antibody CS1002 .
-
Tens of billions of antithrombotic drugs have fallen into the "Altar"! TOP10 rankings have changed, Yangzijiang and others will be the first to imitate
Time of Update: 2021-12-05
The 30 billion market makes waves againSales of Fondaparinux Sodium Injection in Public Medical Institutions in China (Unit: 100 million yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternA few days ago, Yangtze River Jiangsu Zilong Pharmaceutical's Fondaparinux Sodium Injection was approved as a supplementary application, and it is the fourth company that has reviewed the product .
